Copyright 2008 Medical News Today Latest Cervical Cancer / HPV Vaccine News From Medical News Today. http://www.medicalnewstoday.com/sections/cervical_cancer/ admin@medicalnewstoday.com (MNT Admin) editors@medicalnewstoday.com (MNT Editors) en-us Mon, 07 Jul 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/114112.php Predicting a child's future is a near impossible task - today's straight-A student may not become tomorrow's doctor, and the school-yard bully may actually grow up to become a member of the Peace Corps. So why should an adolescent's sexual behavior- or lack thereof - determine whether or not she gets vaccinated against the human papillomavirus, to protect against future HPV infection? It shouldn't, say researchers at the University of Michigan C.S. Sun, 06 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/114016.php Cervical cancer screening needs to take into account a partially-vaccinated population and new technologies, according to an editorial published in the latest edition of Medical Journal of Australia. Dr Annabelle Farnsworth, from Douglass Hanly Moir Pathology, said that although Australia has an enviable record in the control of cervical cancer, there are real benefits in incorporating new knowledge and associated technologies into screening and management of the disease. Thu, 03 Jul 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/113775.php GlaxoSmithKline on Monday said it does not expect to receive FDA approval for its human papillomavirus vaccine Cervarix until late 2009, Reuters reports. GSK said it has decided to wait until results from a Phase III trial of the vaccine are available before seeking U.S. approval. Thu, 03 Jul 2008 05:00:00 PDT http://www.medicalnewstoday.com/articles/113837.php VGX Pharmaceuticals, Inc. (VGX) announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational New Drug (IND) application for its DNA vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. More information on this study is available Thu, 03 Jul 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/113705.php The Royal Society of Health (RSH) welcomes the decision to introduce a national HPV vaccination programme, but with reservations. Responding to the decision taken by the Department of Health last week to use 'Cervarix', one of two HPV vaccines on the market, Professor Richard Parish, RSH Chief Executive said: "The health benefits of vaccination will be considerable, but they could have been much greater. Tue, 01 Jul 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/113353.php GlaxoSmithKline (NYSE: GSK) provided the following update regarding its application to the U.S. Food and Drug Administration (FDA) for approval of CERVARIX(R), its vaccine to prevent cervical cancer. GSK has submitted its response to questions raised by the FDA in their Complete Response Letter, received in December, 2007. Fri, 27 Jun 2008 09:00:00 PDT http://www.medicalnewstoday.com/articles/113026.php The board of the Global Alliance for Vaccines and Immunisation (GAVI) -- a public-private partnership that invests in childhood vaccinations in developing countries -- endorsed a $3.5 billion vaccine investment Fri, 27 Jun 2008 05:00:00 PDT http://www.medicalnewstoday.com/articles/113021.php FDA has delayed a decision on Merck's application to expand marketing of its human papillomavirus vaccine Gardasil to women ages 27 to 45, the company said Wednesday, the Newark Star-Ledger reports (Newark Star-Ledger, 6/26). Tue, 24 Jun 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/112516.php In the United States alone, approximately three-and-a-half million women have abnormal Pap smear tests each year. More than a third of these women develop cervical dysplasia, also known as Cervical Intraepithelial Neoplasia (CIN), a condition caused by the sexually transmitted Human Papilloma Virus (HPV). Stages I & II are considered a precancerous abnormality, but not an actual cancer; stage III is a pre-invasive form of cervical cancer. Mon, 23 Jun 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/112308.php GlaxoSmithKline announced on Wednesday that it has received a three-year contract from the United Kingdom's Department of Health to supply the country's immunization program with its human papillomavirus vaccine Cervarix, the Wall Street Journal reports. The health department's goal is to vaccinate all girls ages 12 to 13 with Cervarix to protect against cervical cancer. GSK will sell Cervarix, administered in a three-shot series, to the state health system. Fri, 20 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/112082.php GlaxoSmithKline's (GSK) cervical cancer vaccine, Cervarix TM, was confirmed as the UK Department of Health's vaccine of choice for its national human papillomavirus (HPV) immunisation programme. The programme, which aims to protect against the two types of HPV that are responsible for approximately 70% of cervical cancers1, will start in September 2008 and will vaccinate girls aged 12 to 13 each year. Thu, 19 Jun 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/111892.php Reacting to today's announcement that the Department of Health is going to use the Cervarix HPV vaccine, that protects young women against cervical cancer in their nationwide vaccination programme, Julie Bentley, Chief Executive fpa said: "While we of course welcome the introduction Thu, 19 Jun 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/111862.php The British Association for Sexual Health and HIV (BASHH) today expressed disappointment that the Government has missed the opportunity to eradicate a common STI, genital warts, from the medical map, as today's announcement by the Department of Health on the human papillomavirus vaccine (HPV), "Department of Health awards contract for HPV vaccine", saw GlaxoSmithKline's vaccine Ceravix awarded the Government contract. Thu, 19 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/111867.php The tender decision made by the UK authorities choosing a two-type (16/18) HPV vaccine for their immunisation campaign means that the girls in this campaign will not benefit from the world's leading four-type (6,11,16,18) HPV vaccine, Gardasil®. Thu, 19 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/111860.php The UK's leading cervical cancer charity, Jo's Trust, has welcomed the Department of Health's announcement that the HPV vaccine, Cervarix will be used in the national immunisation programme for 12/13 year olds starting in September, 2008. Thu, 19 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/111859.php Responding to the announcement by the Department of Health of details of the human papillomavirus (HPV) vaccination programme Simon Blake, Chief Executive of Brook, said: "Brook welcomes confirmation of the details of the HPV vaccination programme from September 2008 that will offer all girls aged 12-13 years vaccination against HPV viruses 16 and 18, the types that lead to increased risk of cervical cancer. Thu, 19 Jun 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/111848.php The contract to provide the vaccine against HPV (human papillomavirus), was awarded by the Department of Health to pharmaceutical company GlaxoSmithKline for their vaccine 'Cervarix'. The contract is to supply the vaccine that protects against cervical cancer and pre-cancerous cell changes in the cervix caused by HPV viruses. Tue, 17 Jun 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/111064.php A study published in the open-access journal PLoS Medicine has found that women in the developing world are not getting the cervical cancer screenings that they need. Researcher Emmanuela Gakidou (University of Washington, Seattle, USA) and colleagues report that although women in the developing world have the highest risk of developing cervical cancer, few are effectively screened. Tue, 10 Jun 2008 06:00:00 PDT http://www.medicalnewstoday.com/articles/110532.php Safety concerns over Merck's human papillomavirus vaccine Gardasil are unfounded, and reports of serious adverse events are unrelated to the vaccine, CDC officials recently said, the Dallas Morning News reports. Sun, 08 Jun 2008 00:00:00 PDT http://www.medicalnewstoday.com/articles/110261.php Merck recently launched a cinema advertising campaign for its human papillomavirus vaccine Gardasil during the opening of the film "Sex and the City," the Newark Star-Ledger reports. The campaign features a 60-second ad similar to the company's "I Chose" television commercial. Sat, 07 Jun 2008 01:00:00 PDT http://www.medicalnewstoday.com/articles/110329.php QIAGEN was featured this week for its efforts to eliminate cervical cancer at the 14th annual Global Summit of Women in Hanoi, Vietnam. CEO Peer Schatz came to this prominent international platform to issue a call to other leaders in business, NGOs and governments to join him and campaign to create a cervical-cancer-free world. Thu, 29 May 2008 02:00:00 PDT http://www.medicalnewstoday.com/articles/109051.php Gen-Probe Incorporated (Nasdaq: GPRO) announced that the Company has launched in Europe its APTIMA(R) HPV Assay, a highly specific molecular diagnostic test to detect high-risk strains of the human papillomavirus (HPV), which causes cervical cancer. The APTIMA HPV Assay has been CE marked and is currently available for sale in 13 European Union countries. Thu, 22 May 2008 04:00:00 PDT http://www.medicalnewstoday.com/articles/108369.php New research into the causes of cervical cancer appears to lend weight to the promise of a potential early detection method that could help prevent the disease. According to a study involving scientists from the University of North Carolina at Chapel Hill, persistent infection with human papillomavirus (HPV) could be a useful clinical marker for increased risk of cervical cancer, the second most common cancer in women worldwide. Thu, 22 May 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/108360.php Long-term data from a study published in the International Journal of Cancer show that women screened only with a human papillomavirus (HPV) DNA test are half as likely to develop moderate to severe cervical disease over the next six years as those who get only conventional cytology (the Pap "smear"). Fri, 16 May 2008 03:00:00 PDT http://www.medicalnewstoday.com/articles/107613.php New data from an extended follow-up study show that CervarixTM generates sustained high levels of neutralising antibodies against the two most common cervical cancer-causing virus types for up to 6.4 years.4 This is the longest duration of sustained neutralising antibody levels reported against both virus types HPV 16 and 18 with a cervical cancer vaccine to date.